Pramlintide

Overview

Pramlintide (brand name Symlin) is a synthetic 37-amino acid analog of human amylin with three proline substitutions that prevent the spontaneous aggregation and fibrillation that occurs with native amylin. It was FDA-approved in 2005 as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes to improve postprandial glycemic control. Beyond glycemic management, pramlintide produces modest but consistent weight loss (1–2 kg in clinical trials) through appetite suppression and gastric emptying delay.

Mechanism of Action

Pramlintide mimics endogenous amylin by binding amylin receptors (calcitonin receptor/RAMP complexes) in the area postrema and hypothalamus. It suppresses postprandial glucagon secretion, slows gastric emptying, and promotes satiety via central nervous system pathways. The combination with mealtime insulin addresses two complementary postprandial metabolic processes: glucose uptake stimulation (insulin) and glucagon suppression/gastric emptying delay (pramlintide), producing more physiological postprandial glucose curves than insulin alone.

Potential Benefits

• Improved postprandial glycemic control in T1D and T2D
• Modest weight loss (1–2 kg)
• Reduced postprandial glucagon excursions
• A1C reduction of 0.5–0.7% as insulin adjunct
• Reduced meal insulin requirements

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

T2D: 60–120 mcg subcutaneously immediately before major meals. T1D: 15–60 mcg before major meals. Start low and titrate to reduce nausea.

Amino Acid Sequence

Side Effects & Safety

• Nausea (most common, especially during initiation)
• Hypoglycemia when used with insulin (requires insulin dose reduction)
• Vomiting
• Anorexia

Synergistic Compounds

The following compounds have been studied alongside Pramlintide for potential complementary or synergistic effects:

Related Peptides

Learn More

References & Further Reading

• [object Object]
• [object Object]